Investors in Axogen, Inc. (NASDAQ:AXGN) had a good week, as its shares rose 6.9% to close at US$42.21 following the release of its second-quarter results. The results were mixed overall, with revenues slightly ahead of analyst estimates at US$70m. Statutory losses by contrast were 5.0% larger than predictions at US$0.03 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

After the latest results, the nine analysts covering Axogen are now predicting revenues of US$279.5m in 2026. If met, this would reflect a notable 11% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 27% to US$0.46. Before this latest report, the consensus had been expecting revenues of US$270.9m and US$0.39 per share in losses. So it's pretty clear the analysts have mixed opinions on Axogen even after this update; although they upped their revenue numbers, it came at the cost of a notable increase in per-share losses.

There was no major change to the consensus price target of US$53.22, with growing revenues seemingly enough to offset the concern of growing losses. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Axogen, with the most bullish analyst valuing it at US$58.00 and the most bearish at US$48.00 per share. This is a very narrow spread of estimates, implying either that Axogen is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Axogen's past performance and to peers in the same industry. It's clear from the latest estimates that Axogen's rate of growth is expected to accelerate meaningfully, with the forecast 24% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 14% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 7.6% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Axogen is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. The consensus price target held steady at US$53.22, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Axogen. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Axogen analysts - going out to 2028, and you can see them free on our platform here.

You still need to take note of risks, for example - Axogen has 2 warning signs we think you should be aware of.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.